We did not evaluate the response and survival endpoints (ORR, PFS, OS) in NSCLC patients presenting different types of EGFR mutations as such data have already been reported elsewhere [58,59], and here we focused on diagnostic issues only. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.